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Oncostatin M Expression Is Functionally Connected
to Neutrophils in the Early Inflammatory Phase
of Skin Repair: Implications for Normal and
Diabetes-Impaired Wounds
Itamar Goren1, Heiko Ka¨mpfer1, Elke Mu¨ller1, Dana Schiefelbein1, Josef Pfeilschifter1 and Stefan Frank1
In this study, we investigated the role of the cytokine oncostatin M (OSM) for wound biology. OSM and its
specific OSM receptor subunit b (OSMRb) were induced upon injury. OSM induction paralleled the early influx
of polymorphonuclear neutrophils (PMN) into the wound. OSM protein was localized in PMN in very early
wounds, whereas OSMRb could be detected on macrophages, keratinocytes, and fibroblasts later in repair. To
establish a functional connection between PMN and OSM expression in wounds, we depleted mice from
circulating PMN by injecting an anti-PMN monoclonal antibody (Ly-6G). PMN-depleted wounds were
characterized by a nearly complete loss of OSM but not OSMRb mRNA and protein expression within the
initial 16–24 hours after injury. PMN-rich chronic wounds from diabetic ob/ob mice were characterized by a
strongly elevated OSM mRNA and protein expression as compared to healthy animals. Moreover, a leptin-
mediated improvement of chronic wounds in ob/ob mice was paralleled by a complete inhibition of PMN influx
associated again with a dramatic loss of OSM expression at the wound site. These data constitute strong
evidence that OSM expression during wound inflammation is functionally connected to PMN infiltration.
Journal of Investigative Dermatology (2006) 126, 628–637. doi:10.1038/sj.jid.5700136; published online 12 January 2006
INTRODUCTION
Skin repair represents a highly dynamic process involving
fibroplasia, angiogenesis, and neo-epithelialization para-
lleled by a tightly controlled gene expression at the wound
site. Especially wound inflammation is established to initiate
and drive skin regeneration (Martin, 1997; Singer and Clark,
1999; Werner and Grose, 2004). However, the importance of
wound inflammation is double-faced. Chronic wound situ-
ations in humans and mice are associated with conditions of
prolonged and dysregulated inflammation (Rosner et al.,
1995; Loots et al., 1998; Wetzler et al., 2000; Goren et al.,
2003). Therefore, deeper insights into underlying mecha-
nisms with respect to wound inflammatory processes are
pivotal to the future understanding of disturbed healing
conditons (Jeffcoate and Harding, 2003).
Here, we have identified a dysregulated expression of
oncostatin M (OSM) in chronic wounds of diabetic mice.
OSM represents a multifunctional 28 kDa cytokine that
belongs to the IL-6 family of proteins (Tanaka and Miyajima,
2003) and is produced from activated T- and monocytic cell
types (Zarling et al., 1986; Brown et al., 1987; Malik et al.,
1989; Wallace et al., 1999). Additionally, also polymorpho-
nuclear neutrophils (PMN) have been recently described to
be potent cellular sources of OSM biosynthesis and release
under inflammatory conditions (Grenier et al., 1999; Hurst
et al., 2002). OSM participates in growth regulation,
differentiation, gene expression, and cell survival in a variety
of cell types and, remarkably, also contributes to inflamma-
tion and tissue remodeling processes (Tanaka and Miyajima,
2003).
Biologic activities of OSM are mediated through binding
to its specific OSM receptor subunit b (OSMRb), which
belongs to the signal transducing receptors for IL-6 type
cytokines (Heinrich et al., 2003). Cloning and expression of
the OSMRb revealed that OSM restrictively transduces
signals through its specific receptor complex composed of
gp130 and OSMRb (Mosley et al., 1996; Lindberg et al.,
1998; Tanaka et al., 1999). The OSMRb subunit is widely
expressed in various cell types and tissues, including
epithelial cells, fibroblasts, and skin tissue (Mosley et al.,
1996). It is important to note that its specific ligand OSM
exerts potential functions in the skin, as this cytokine
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stimulates mitogenic responses of dermal fibroblasts,
dermal endothelial cells (Vasse et al., 1999; Ihn and
Tamaki, 2000) and extravasation of PMN into skin
tissue after subcutaneous application (Modur et al.,
1997).
Here, we report evidence for a functional coupling of
OSM to PMN infiltration in very early wounds. Moreover, we
demonstrate that a leptin-improved healing of chronic
wounds was associated with a dramatic loss of PMN cell
numbers and OSM expression at the wound site. Thus, this
study provides evidence that dysregulated OSM expression is
functionally connected to the PMN wound infiltrate and
associated with impaired healing conditions in chronically
inflamed wounds.
RESULTS
OSM and OSMRb expression in normal skin repair
OSM has been shown to be produced by inflammatory cell
types such as monocytes and PMN under inflammatory
conditions (Malik et al., 1989; Wallace et al., 1999; Grenier
et al., 1999; Hurst et al., 2002). As wound inflammation
represents a pivotal process for skin regeneration (Martin,
1997), we first determined expression of OSM and its specific
receptor subunit OSMRb in undisturbed skin repair. As
shown in Figure 1a, OSM mRNA levels were induced upon
injury. The very rapid increase of OSM mRNA levels in early
repair was dramatic as compared to the observed low-level
expression in non-wounded skin (35.273.1-fold; Po0.05 as
compared to control skin). Accordingly, OSM protein
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Figure 1. Expression of OSM and its OSMRb in skin repair. Regulation of (a) OSM and (b) OSMRb mRNA (upper panels) and protein (lower panels) expression
in C57 Bl/6 mice as assessed using the RNase protection assay or immunoblot. The time after injury is indicated at the top of each lane. Ctrl skin refers to back
skin biopsies of non-wounded mice. 1,000 cpm of the hybridization probe were added to the lane labeled probe. Additional bands in the probe lane represent
truncated RNA transcripts. A quantification of OSM and OSMRb mRNA (x-fold of control skin) is shown in the middle panels. *Po0.05 (analysis of variance,
Dunnett’s method) as compared to control skin. Bars indicate the mean7SD obtained from wounds (n¼48) isolated from animals (n¼ 12) from three
independent animal experiments. For immunoblot analysis, each time point depicts eight wounds (n¼ 8) from four individual mice (n¼ 4). Two independent
experimental animal series (#1, #2) are shown. Loading of immunoblots and protein integrity was controlled using actin immunodetection or Ponceau S staining
as indicated. Here, it is important that the observed increase in actin expression after wounding is always observed in the dynamic process of skin repair and is
not because of unequal loading of the analyzed wound lysates.
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expression was hardly detectable in non-wounded skin.
However, wounding induced the induction of OSM protein,
which appeared in marked amounts especially during early
wound inflammation (days 1 and 3 post-wounding) (Figure
1a, lower panels). To complement the data on OSM
expression, we also determined the regulation of its specific
receptor at the wound site. Although the overall changes in
mRNA and protein expression were only moderate compared
to OSM regulation, we observed a clear induction of OSMRb
mRNA (2.970.6-fold; Po0.05 as compared to control skin)
(Figure 1b, upper panels) and protein (Figure 1b, lower
panels) expression upon injury. Induction of OSMRb
occurred rapidly after wounding, but by contrast to OSM,
the increase in OSMRb protein persisted into later stages of
repair (Figure 1b, lower panels). Here, it is important to note
that RNase protection assay detected an additional specific
band which must represent a splice variant of the published
OSMRb transcript. Interestingly, the truncated mRNA trans-
cript occurred to be constitutively present during repair
(Figure 1b, upper panel). The observed molecular weight of
approximately 180 kDa for the OSMRb subunit in SDS-PAGE
was in good accordance to three reports showing the cloning
and expression of the protein (Mosley et al., 1996; Lindberg
et al., 1998; Tanaka et al., 1999).
Localization of OSM and its OSMRb subunit at the wound site
As a next step, we determined the cellular sources of OSM
and OSMRb expression during repair. Double staining of
wound serial sections showed that early wound tissue
(24 hours after injury) was characterized by OSM expressing
PMN (Figure 2a–c). During a later stage of healing (day 3
post-wounding), we observed that OSM was not only
expressed in PMN, as a different nuclear morphology
identified also a macrophage (Mf) subset of infiltrating
immune cells to express OSM at the wound site (Figure 2e). In
line with the disappearance of OSM at later stages of repair
(Figure 1a), we could detect only a few OSM-positive cells
within the granulation tissue of 5-day wounds (Figure 2f).
However, immunohistochemistry suggested also wound
margin keratinocytes as potential producers of OSM (Figure
2f and g), which might contribute to the overall decreasing
and weak expression of OSM at that stage of repair (Figure 1a,
lower panels). We performed a pre-incubation of the anti-
OSM antiserum with recombinant murine OSM protein
before immunohistochemistry to block and thus control
specific antibody binding to OSM antigens in tissue sections
(Figure 2d and h).
OSMRb localization at the wound site appeared to be
diverse. We detected OSMRb to be expressed in a subset of
infiltrating immune cells in early (3 days) and later healing (7
days). Owing to nuclear morphology, these OSMRb-positive
cells were most likely Mf rather than the PMN cell type of
the infiltrate (Figure 3a, e, g and h). Moreover, the absence of
PMN, which have disappeared from the wound at this stage
of repair in undisturbed 7-day wounds (Wetzler et al., 2000),
again strongly argued for OSMRb-expressing Mf. Addition-
ally, we could also observe fibroblasts (Figure 3b) and
keratinocytes (Figure 3c and d) to express OSMRb during
repair. An unspecific goat IgG incubation (Figure 3f) served as
negative control.
OSM is preferentially expressed in inner wound areas (granu-
lation tissue)
To strengthen the histologic data concerning the cellular
sources of OSM expression, we now analyzed the expression
of OSM in distinct compartments of wound tissue (Figure 4a).
Tissue was taken from 3-day wounds and divided into
‘‘wound margin’’ tissue (which contained part of the non-
wounded epidermis and dermis, and, more importantly, the
complete developing wound margin epithelia) and the ‘‘inner
wound’’ (which contained the complete developing granu-
lation tissue consisting of PMN, Mf, fibroblasts, and endo-
thelial cells). We found OSM mRNA (Figure 4b) and protein
(Figure 4c) to be predominantly expressed in the inner wound
compartment (inner wound 4437139 Phospholmager photo-
stimulated luminescence (PSL) counts versus 13175.3 PSL
counts in wound margins, Po0.05). This result was in good
accordance to our observation of OSM-expressing immune
cells (Figure 2), which are predominantly localized within the
granulation tissue. A recombinant 21.0 kDa truncated murine
PMN OSM
OSM
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Figure 2. Localization of OSM protein in regenerating skin. Frozen serial
sections from mouse wounds (days 1, 3, and 5 post-wounding) were
incubated with a polyclonal goat antiserum directed against murine OSM or
with a monoclonal antibody against PMN-specific Ly-6G as indicated. All
sections were stained with the avidin–biotin–peroxidase complex system using
3,3-diaminobenzidine-tetrahydrochloride as a chromogenic substrate. Nuclei
were counterstained with hematoxylin. Immunopositive signals within the
sections are indicated with arrows. Specificity of the anti-OSM antiserum
(OSM negative control) was controlled by pre-adsorption of the antiserum
using a recombinant OSM protein. gt, granulation tissue; he,
hyperproliferative epithelium.
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OSM protein and an unspecific control IgG was used to
control the specificity of the anti-OSM antiserum (Figure 4d,
lower panel).
Depletion of early wound tissue from PMN severely inhibited
expression of proinflammatory cytokines and OSM at the
wound site
As we had identified PMN as producers of OSM in initial
wound healing, we now tried to prove a direct functional
connection between OSM expression and early PMN influx
in early wound repair. To do so, we treated healthy mice by
systemic injection of the rat monoclonal antibody Ly-6G
(1 mg/g body weight, once a day) two days before wounding.
This antibody specifically recognizes the GR-1 epitope on
murine PMN and has been described to cause a long-lasting
neutropenia when injected into mice (Thakur et al., 1996).
First, we controlled the neutropenic efficiency of treatment.
Neutropenic treatment of mice with the anti-Ly-6G antibody
was very efficient, as we could not detect any PMN-specific
signals in early wound tissue (Figure 5a, upper panel). Using
immunoblot analysis, we observed infiltrating Mf (as
assessed by the Mf-specific F4/80 antibody) after 16 and
24 hours under both conditions of treatment (Figure 5a, lower
panel). However, it is important to note that immunoblotting
using the F4/80 antibody appeared to be limited with respect
to sensitivity. Thus, we have alternatively determined
lysozyme M mRNA expression, which is known to be
constitutively expressed in Mf and can be used to determine
the presence of this cell type in wound tissue (Wetzler et al.,
2000; Goren et al., 2003). As shown in Figure 5b, we could
indeed detect the presence of tissue Mf in non-wounded
control skin. Wounding induced a slow and moderate
increase in Mf numbers as compared to 3-day wounds,
which are characterized by highest Mf cell numbers in skin
repair (diPietro, 1995; Wetzler et al., 2000; Goren et al.,
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Figure 3. Localization of OSMRb protein in regenerating skin. Frozen serial
sections from mouse wounds (days 3, 5, and 7 post-wounding) were
incubated with polyclonal goat antiserum directed against murine OSMRb
as indicated. All sections were stained with the avidin–biotin–peroxidase
complex system using 3,3-diaminobenzidine-tetrahydrochloride as
a chromogenic substrate. Nuclei were counterstained with hematoxylin.
Immunopositive signals within the sections are indicated with arrows.
Specificity of the goat anti-OSMRb antiserum (OSMRb negative control) was
controlled by incubation of the tissue section using an unspecific goat IgG.
gt, granulation tissue; he, hyperproliferative epithelium; hf, hair follicle.
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Figure 4. Spatial distribution of OSM expression in wound tissue.
(a) Overview to show tissue sampling for inner wound (iw) and wound margin
(m). (b) OSM mRNA and (c) protein expression in 3-day wound margin and
inner wound isolated from C57 Bl/6 wild-type mice assessed using the RNase
protection assay or immunoblot. (b) For mRNA expression, we have analyzed
one wound each isolated from three individual animals (n¼3) per
independent experimental series. Every data point depicts the OSM-specific
signal from three wound compartments isolated from three individual mice
(n¼3) which have been pooled before analysis. Bars (mean7SD) indicate
data obtained from three independent animal experiments (n¼3) that have
been used for statistical analysis. *Po0.05 as indicated by the bracket. For
immunoblot analysis, each time point depicts isolated wound compartments
of six wounds (n¼6) from three individual mice (n¼3). Immunodetection of
actin was used to control equal loading. (d) Specificity of the used anti-OSM
antiserum was confirmed using a 21 kDa truncated recombinant murine OSM
protein (rOSM) (middle panel) and by re-probing the same immunoblot using
a normal IgG in combination with the same secondary antibody (lower
panels).
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2003). Not unexpected, however, we did not observe an
effect of the Ly-6G antibody on the presence of Mf in early
wounds (Figure 5b).
As PMN have been established as the first producers of
proinflammatory cytokines within the first 24 hours at the
wound site (Hu¨bner et al., 1996), we additionally determined
mRNA expression for IL-1b and tumor necrosis factor (TNF) a
as indicated. Transcripts of both cytokines were down-
regulated in PMN-depleted wound conditions (Figure 5c,
upper panels) suggesting that infiltrating PMN might be
functionally connected to an early cytokine expression
following injury in the presence of unchanged vascular
endothelial growth factor and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA levels (Figure 5b, lower
panels).
In line with the effects of PMN depletion on cytokine
expression, we found also OSM expression to be dependent
on early PMN infiltration (Figure 6). We observed a marked
downregulation of OSM mRNA (phosphate-buffered saline
(PBS)-treated 168773 PSL counts versus Ly-6G 39719 PSL
counts, Po0.05) (Figure 6a) and OSM protein (Figure 6b)
expression in very early wounds of Ly-6G-treated mice.
Remarkably, PMN-mediated differences in OSM protein
levels diminished after 24 hours (Figure 6b, 24 hours wound),
here suggesting that the re-appearance of OSM protein at this
time point of healing might be linked to Mf (Figure 5a and b),
which have been shown to express OSM (Figure 2e).
Interestingly, expression of the OSM-specific OSMRb subunit
mRNA (PBS-treated 165736 PSL counts versus Ly-6G
156718 PSL counts) (Figure 7a) and protein (Figure 7b)
was not changed under the same experimental conditions in
PMN-depleted wounds. A normal goat IgG control revealed
the specificity of the anti-OSMRb immunoblot (data not
shown).
Improved healing of chronic wounds in diabetic ob/ob mice is
associated with a dramatic downregulation of OSM expression
and PMN influx
Finally, we investigated the expression of OSM during skin
repair in ob/ob mice. Ob/ob animals are characterized by a
type II diabetes (Coleman, 1978) and develop severely
impaired wound healing conditions after injury (Frank
et al., 2000) associated with highly elevated numbers of
PMN and Mf (Goren et al., 2003). As shown in Figure 8a,
fully developed 13-day chronic wounds in ob/ob mice were
clearly characterized by markedly elevated levels of OSM
mRNA (for OSM mRNA in 13-day wounds in control mice
refer to Figure 1a) and protein as compared to healthy C57 Bl/
6 animals. As a next step, we treated ob/ob mice with
recombinant leptin (2 mg/g body weight/day) during the
healing period. Here, it is important to note that a distinct
difference in PMN infiltrate between diabetes-impaired and
leptin-improved healing in ob/ob mice is restricted to the late
healing time point (day 13 post-wounding) (Goren et al.,
2003). Accordingly, leptin treatment markedly downregu-
lated elevated OSM mRNA (PBS-treated 191746 PSL counts
versus leptin 52720 PSL counts, Po0.01) and protein levels
during improved repair in late 13-day wounds (Figure 8b). In
good accordance to the observed functional coupling
between wound PMN and OSM levels, we determined the
complete absence of infiltrating PMN in the presence of again
dramatically reduced OSM levels (Figure 8c, left panels).
Interestingly, PMN can be located in complete wound
tissue including the wound scab (Figure 8d). Moreover,
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Figure 5. Systemic treatment of mice with an anti-Ly-6G antibody depletes
wound tissue from PMN and cytokine expression. (a) Immunoblots showing
the presence of PMN (upper panels, as assessed by Ly-6G) or Mf (as assessed
by F4/80) in wounds of Ly-6G-induced neutropenic or mock-treated control
mice as indicated. For immunoblot analysis, each time point depicts eight
wounds (n¼8) from four individual mice (n¼ 4). Loading of immunoblots
and protein integrity was controlled using a Ponceau S staining. Regulation of
(b) lysozyme M, or (c) IL-1b, TNF-a, vascular endothelial growth factor, and
GAPDH mRNA expression in wounds of Ly-6G-induced neutropenic or
mock-treated control mice as indicated. The time after injury is given at the
top of each lane. Ctrl skin refers to back skin biopsies of non-wounded mice.
One thousand cpm of the hybridization probe were added to the lane labeled
probe.
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leptin-mediated changes in OSM expression were most likely
independent from Mf in diabetic wounds, as leptin-mediated
OSM changes occurred in the presence of an unaltered
infiltration of Mf (Figure 8c, right panels). Finally, we did not
observe an overall change in OSMRb mRNA expression in
chronic versus leptin-improved repair at day 13 post-
wounding (PBS-treated 131728 PSL counts versus leptin
136720 PSL counts, not significant) (Figure 8e). However,
the kinetics of OSMRb protein expression during impaired
healing was clearly different to that observed in normal skin
repair (Figure 8f; for normal repair, refer to Figure 1b).
DISCUSSION
Diabetic ulcerations represent severely disturbed healing
conditions in injured skin tissue that are associated with a
dramatically exacerbated and prolonged inflammation at the
wound site (Rosner et al., 1995; Loots et al., 1998; Wetzler
et al., 2000; Goren et al., 2003). Within this context, it was
quite remarkable to identify OSM as a potentially dysregu-
lated factor from inflamed, chronic wound tissue which has
been isolated from diabetic ob/ob mice. OSM is now
suggested to participate in dynamic processes such as growth
regulation, differentiation, inflammation, and tissue remodel-
ing (Tanaka and Miyajima, 2003). OSM has been described
to inhibit the growth of carcinoma cell lines (Brown et al.,
1987). Therefore, it is tempting to speculate that appearance
of OSM within the initial 48 hours of repair might function to
inhibit early keratinocyte proliferation, which is delayed after
injury to allow the cells to migrate into the area of injury
(Clark, 1996). In line, we observed a disappearing OSM in
overlap with the development of the massive wound margin
epithelia (Singer and Clark, 1999). A second line of evidence
supports an additional role of OSM in wound biology. OSM
has been shown to serve as a potent mitogen for isolated
human dermal fibroblasts and human dermal microvascu-
lature endothelial cells (Vasse et al., 1999; Ihn and Tamaki,
2000) and to induce vascular endothelial growth factor in
smooth muscle or monocytic cell types (Repovic et al., 2003;
Faffe et al., 2005). In line with these reports, we found OSM
to be expressed in inner wound areas, exactly where
fibroplasia and neo-vascularization takes place. In accord-
ance, this observation suggests that the observed increase in
OSM in late disturbed wound tissue might be an adaptive
regulatory process to compensate for the reduced mitogenic
responses of wound fibroblasts and endothelial cells.
Three major cell types are established as producers of
OSM under different conditions in vitro and in vivo: activated
T lymphocytes (Brown et al., 1987), activated monocytic
cells (Zarling et al., 1986; Wallace et al., 1999), and PMN
(Grenier et al., 1999; Hurst et al., 2002). In good accordance,
we could actually immunolocalize PMN and Mf, respec-
tively, in the very initial and early phases of wound
inflammation using an OSM-specific antiserum. PMN repre-
sent the very first immune cells, infiltrating within minutes
into the area of injury (Martin, 1997; Singer and Clark, 1999).
We could confirm the very early appearance of this cell type
in our study, as we observed a very prominent and
pronounced PMN-specific signal in wound lysates 5 hours
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Figure 6. Wounds of neutropenic mice are characterized by strongly reduced OSM levels. (a) Regulation of OSM mRNA expression in wounds of Ly-6G-
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mice as indicated. For immunoblot analysis, each time point depicts eight wounds (n¼8) from four individual mice (n¼ 4). Two independent animal
experiments (#1, #2) are shown. Loading of immunoblots and protein integrity was controlled using actin immunodetection or Ponceau S staining as indicated.
Here, it is important that the observed increase in actin expression after wounding is always observed in the dynamic process of skin repair and is not because of
unequal loading of the analyzed wound lysates.
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following injury. With respect to published data, we
hypothesized that the rapid increase in wound OSM levels
might be connected, at least partially, to the early PMN
wound infiltrate, as PMN have been described to carry
intracellular stores of biologically active OSM (Grenier et al.,
1999). Interestingly, we could observe a nearly complete loss
of OSM protein in PMN-depleted early wounds from
neutropenic mice after injection of the anti-PMN antibody
Ly-6G. This antibody has been convincingly demonstrated to
induce severe neutropenic states in mice in a dose-dependent
manner (Thakur et al., 1996).
Here, it is reasonable to argue that the overall loss of OSM
protein at the wound site must be a functional consequence
of the missing PMN infiltrate at the early site of injury. This
observation indicates an important role of this cell type in
very early tissue regeneration. With respect to our data it must
remain unclear, however, to what extent a direct effect on
PMN-expressed and secreted OSM contributed to the
observed loss of OSM in early wounds. As we had observed
PMN as producers of OSM by immunohistochemistry, it now
comes clear that at least a part of the observed wound-
specific OSM is imported by this specific subset of immune
cells into the wound site as a stored cytokine ‘‘cargo’’. By
contrast, we cannot exclude that a PMN-driven OSM
expression by resident wound cells might also contribute to
the observed effects. Moreover, the observation that PMN
express IL-1b and TNF-a in wound tissue (Hu¨bner et al.,
1996) might also explain the strong attenuation of IL-1b and
TNF-a in PMN-depleted early wounds, which again supports
the ‘‘cargo’’-principle in PMN with respect to these cyto-
kines. Additionally, the observed attenuation of IL-1b and
TNF-a expression in PMN-depleted wound tissue implicates
that the very early wound response was not augmented by an
increased bacterial infection in the absence of microbicidal
PMN. In good accordance with early wound conditions, we
observed a decrease in OSM expression in PMN-diminished
late healing wounds of leptin-treated ob/ob mice. Here, it is
suggested that leptin might contribute to this process via its
effects on wound keratinocytes, as it turns off the expression
of PMN-attracting CXC-chemokines in neo-epithelia in vivo
(Goren et al., 2003).
Finally, one question still remains: what functions might
be served by OSM in the control of wound inflammation?
Interestingly, some properties of OSM for skin inflammation
have been shown by a subcutaneous injection of human
recombinant OSM into mice (Modur et al., 1997). In this
animal model, human OSM induced a local inflammatory
response including the extravasation of PMN. Moreover,
OSM was highly selective for PMN recruitment (Kerfoot
et al., 2001), capable to induce the endothelial transmigra-
tion of PMN via induction of different selectins, and efficient
to mediate the synthesis of PMN-attracting chemokines at the
site of inflammation (Modur et al., 1997; Kerfoot et al., 2001).
However, consequences of these data have to be interpreted
very carefully with respect to functional properties of OSM in
cutaneous inflammation. A paper by Lindberg et al. (1998)
convincingly showed that human OSM restrictively signaled
through receptors containing the LIFRb and gp130, but not
through the mouse OSMRb subunit. That means that the
above mentioned study of human OSM actions in murine
skin (Modur et al., 1997) did not elucidate the biology of
OSM but reflected the biological actions of LIF. Nevertheless,
OSM functions have to be potentially interpreted as proin-
flammatory in the skin organ system. This hypothesis is
further strengthened by our observation that highly inflamed
diabetes-impaired wounds were clearly characterized by a
marked overexpression of the cytokine OSM.
In summary, this study provides evidence that OSM
contributes to wound inflammation under normal, but also
impaired healing conditions. OSM expression was function-
ally connected to the early PMN infiltrate. Thus, our data
strongly support an important role of the early PMN infiltrate
in the regulation and biosynthesis of cytokines in cutaneous
wound healing.
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MATERIALS AND METHODS
Animals
Female C57BL/6J (wild type) and C57BL/6J-ob/ob mice were
obtained from The Jackson Laboratories (via Charles River, Sulzfeld,
Germany) and maintained under a 12 hours light/12 hours dark cycle
at 221C until they were 8 weeks of age. At this time they were caged
individually, monitored for body weight, and wounded as described
below.
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Treatment of mice
Murine recombinant leptin (2mg/g body weight) (Calbiochem, Bad
Soden, Germany) and purified rat monoclonal anti-PMN antibody
Ly-6G (Thakur et al., 1996) (1mg/g body weight) (BD Pharmingen,
Heidelberg, Germany) were injected intraperitoneally in 0.5 ml PBS
for the indicated time periods. Control mice were treated with PBS or
an unspecific rat IgG (Santa Cruz. Heidelberg, Germany), respec-
tively.
Wounding of mice
Wounding of mice was performed as described previously (Frank
et al., 1999; Stallmeyer et al., 1999). Briefly, mice were anesthetized
with a single intraperitoneal injection of ketamine (80 mg/kg body
weight)/xylazine (10 mg/kg body weight). The hair on the back of
each mouse was cut, and the back was subsequently wiped with
70% ethanol. Six full-thickness wounds (5 mm in diameter, 3–4 mm
apart) were made on the back of each mouse by excising the skin
and the underlying panniculus carnosus. The wounds were allowed
to form a scab. Skin biopsy specimens were obtained from the
animals 1, 3, 5, 7, 10, and 13 days after injury. At each time point,
an area which included the scab and the complete epithelial margin
was excised from each individual wound. The scab was included for
analysis as it covers immune cells and bioactive mediators (Goren
et al., 2003). As a control, a similar amount of skin was taken from
the backs of non-wounded mice. For each experimental time point
of every individual animal experiment, tissue from four wounds each
from four animals (n¼ 16 wounds, RNA analysis) and from two
wounds each from four animals (n¼ 8 wounds, protein analysis)
were combined and used for RNA and protein preparation.
Pooling of wound samples guarantees the experimental basis to
determine a consistent and reliable expression pattern for genes and
proteins of interest between different individual animal experiments.
Non-wounded back skin from four animals served as a control. Data
from at least three individual animal experiments were used to
perform the statistical evaluations. All animal experiments were
carried out according to the Declaration of Helsinki Principles and
with the permission from the local government of Hessen
(Germany).
RNA isolation and RNase protection analysis
RNA isolation and RNase protection assays were carried out as
described previously (Chomczynski and Sacchi, 1987; Frank et al.,
1999). Briefly, 20 mg of total RNA from wounded or non-wounded
skin was used for RNase protection assay. DNA probes were cloned
into the transcription vector pBluescript II KS(þ )(Stratagene,
Heidelberg, Germany) and linearized. An antisense transcript was
synthesized in vitro using T3 or T7 RNA polymerase and [a-32P]UTP
(800 Ci/mmol). RNA samples were hybridized at 421C overnight
with 100.000 cpm of the labeled antisense transcript. Please note
that we always used cocktails of labeled antisense transcripts: the
probes of interest and the GAPDH equilibration antisense transcipts
were simultaneously hybridized in the same sets of total RNA in all
presented RNase protection assays. Hybrids were digested with
RNases A and T1 for 1 hour at 301C. Under these conditions, every
single mismatch is recognized by the RNases. Protected fragments
were separated on 5% acrylamide/8 M urea gels and analyzed using
a PhosphoImager (Fuji, Straubenhardt, Germany). Subsequently, the
probe of interest and the GAPDH equilibration marker were
separated on the same gel for each individual experimental
approach that allows for a direct and reliable loading control in all
experiments. RNases A and T1 were from Roche Biochemicals
(Mannheim, Germany). The murine cDNA probes were cloned using
reverse transcription-PCR. The probes corresponded to nt 303–546
(for OSM, Acc. No. D31942), nt 389–645 (for OSMRb, Acc. No.
NM011019), nt 481–739 (for IL-1b, Acc. No. NM0083461), nt
541–814 (for TNF-a, Acc. No. NM013693), nt 139–544 (for vascular
endothelial growth factor, Acc. No. M95200), nt 816–1481 (for
lipocalin, Acc. No. X81627), nt 425 (exon 1) to 170 (exon 2) (for
lysozyme M, Acc. No. M21047), nt 796–1063 (for cyclooxygenase
[COX]-2, Acc. No. M64291), or nt 163–317 (for GAPDH, Acc. No.
NM002046) of the published sequences.
Immunoblot analysis
Wound tissue lysates were prepared as described previously
(Ka¨mpfer et al., 1999). Briefly, skin samples were homogenized in
lysis buffer (1% Triton X-100, 20 mM Tris/HCl, pH 8.0, 137 mM NaCl,
10% glycerol, 5 mM ethylenediamine tetraacetic acid, 1 mM phenyl-
methylsulfonyl fluoride, 5 mg/ml aprotinin, 5mg/ml leupeptin). The
extracts were cleared by centrifugation. Fifty micograms of total
protein lysate was separated using SDS-gel electrophoresis and
specific proteins were detected using antisera directed against OSM
or OSMRb (Santa Cruz, Heidelberg, Germany), respectively. The
specificity of the anti-OSM antiserum was confirmed using a
truncated murine recombinant OSM protein (21 kDa, Ala26-
Arg207) (R&D Systems, Wiesbaden, Germany). A secondary anti-
body coupled to horseradish peroxidase and the enhanced chemi-
luminescence detection system was used to visualize the proteins of
interest. Phenylmethylsulfonyl fluoride, aprotinin and leupeptin were
from Sigma (Deisenhofen, Germany) or Roche Biochemicals
(Mannheim, Germany). The enhanced chemiluminescence detection
system was obtained from Amersham (Freiburg, Germany).
Immunohistochemistry
Mice were wounded as described above. Animals were killed at
days 1, 3, 5, and 7 after injury. Complete wounds were isolated from
the back, bisected, and frozen in tissue freezing medium. Six micron
frozen sections were subsequently analyzed using immunohisto-
chemistry as described (Stallmeyer et al., 1999). Polyclonal antisera
against OSM and the OSMRb (Santa Cruz, Heidelberg, Germany)
were used for immunodetection. Specificity of the goat anti-OSM
antibody was controlled by a 2 hours pre-incubation of the antibody
with a truncated murine recombinant OSM protein (21 kDa, Ala26-
Arg207) (R&D systems, Wiesbaden, Germany) before its exposure to
wound tissue sections. The pre-adsorption blocks and thus controls
the specific binding of the anti-OSM antiserum. The goat anti-
OSMRb was controlled using an incubation of tissue sections with
an unspecific goat IgG (Santa Cruz, Heidelberg, Germany) before
incubation with the secondary antibody, as a recombinant OSMRb
protein was not available.
Statistical analysis
Data are shown as means7standard deviation (SD). Data analysis
was carried out using the unpaired Student’s t-test with raw data.
Statistical comparison between more than two groups was carried
out by analysis of variance (analysis of variance, Dunnett’s method).
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